10 recruiting, 6 completed, 5 terminated, 1 not yet recruiting. 23 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Recruiting 10, Completed 6, Terminated 5, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 8 | Recruiting 6, Completed 1, Not yet recruiting 1 |
Follow Rescue medication: new trials by email Literature Review of Rescue medication trials Research Report on Rescue medication
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) Sacituzumab tirumotecan, Rescue medication, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 290 | 2026-12-14 | 2026-11-02 |
| A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007) MK-6916, Hydrocodone/acetaminophen (HB/APAP), MK-6916 Placebo - Pain Management | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 380 | 2026-11-02 | 2026-11-17 |
| A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) I-DXd, Rescue Medication - Oesophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 60 | 2026-03-27 | 2026-11-10 |
| KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) MK-3120, EV, Pembrolizumab - Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 55 | 2026-02-09 | 2026-10-02 |
| KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) MK-1084, Pembrolizumab, Cetuximab - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 140 | 2025-12-19 | 2026-11-10 |
| Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) Pembrolizumab, I-DXd, Leucovorin - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 298 | 2025-07-30 | 2026-11-13 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) R-DXD, I-DXD, Docetaxel - Lung Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 144 | 2025-05-28 | 2026-11-13 |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). Raludotatug Deruxtecan, Carboplatin, Paclitaxel - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 605 | 2025-04-15 | 2026-11-13 |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) Zilovertamab vedotin, Rituximab, Cyclophosphamide - Lymphoma, Large B-Cell, Diffuse | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 594 | 2025-04-11 | 2026-11-13 |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Sacituzumab tirumotecan, Rescue medication, Supportive care measures - Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 35 | 2024-12-20 | 2026-11-05 |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin - Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 220 | 2024-06-20 | 2026-10-29 |
| Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD) Danirixin, Placebo, Rescue medication - Pulmonary Disease, Chronic Obstructive | Phase 2 | Terminated | GlaxoSmithKline | 19 | 2017-11-15 | 2021-03-29 |
| A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD) Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device - Pulmonary Disease, Chronic Obstructive | Phase 2 | Terminated | GlaxoSmithKline | 54 | 2017-10-16 | 2020-07-31 |
| Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD) Danirixin, Danirixin matching placebo, Standard of care - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | GlaxoSmithKline | 614 | 2017-04-25 | 2020-10-28 |
| A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma Sirukumab, Placebo, Rescue medication - Asthma | Phase 2 | Withdrawn | GlaxoSmithKline | 2016-09-23 | 2018-08-31 | |
| A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma 800 μg AZD7594 once daily, 250 µg AZD7594 once daily, 58 µg AZD7594 once daily - Asthma, Efficacy | Phase 2 | Completed | AstraZeneca | 54 | 2015-06-25 | 2018-02-15 |
| A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007) MK-1602, Placebo, Rescue medication - Migraine | Phase 2 | Completed | Allergan | 195 | 2012-08-01 | 2016-12-09 |
| A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006) MK-1602, Placebo-matching MK-1602, Rescue medication - Migraine | Phase 2 | Completed | Allergan | 834 | 2012-07-01 | 2019-01-08 |
| Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) Fosaprepitant dimeglumine, 5-HT3 RA, Dexamethasone - Nausea, Vomiting | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 111 | 2011-10-25 | 2018-08-27 |
Showing 20 of 23. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (5) · Asthma (2) · Esophageal Squamous Cell Carcinoma (2) · Migraine Disorders (2) · Agnosia (1) · Biliary Tract Neoplasms (1) · Colorectal Neoplasms (1) · Disease Progression (1) · Lung Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Nausea (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Merck Sharp & Dohme LLC (16) · GlaxoSmithKline (4) · Allergan (2) · AstraZeneca (1)
United States (14) · Spain (9) · South Korea (8) · Chile (7) · United Kingdom (7) · Germany (6) · Italy (6) · Canada (5) · China (5) · France (5) · Israel (5) · Netherlands (5) · Poland (5) · Taiwan (5) · Turkey (Türkiye) (5)
Andrea Ludwig-Sengpiel, Dr. (1) · Anne-Marie Kirsten, Dr. (1) · Anneliese Linnhoff, Dr. med. (1) · Christine Grigat, Dr. (1) · Dirk Skowasch, Prof. (1) · Jutta Beier, Dr. med. (1) · Margret Jandl, Dr. (1) · Oliver Kornmann, Dr. (1) · Rainard Fuhr, Dr. med. (1) · Tanya Kralimarkova, Dr. (1) · Ulrike Westerhausen, Dr. (1)
PMID 22702508, PMID 25695403, PMID 30777086, PMID 39982105
2025 (2), 2005 (1), 2008 (1), 2014 (1), 2016 (1), 2017 (1), 2023 (1)